» Articles » PMID: 22558363

Features of Idebenone and Related Short-chain Quinones That Rescue ATP Levels Under Conditions of Impaired Mitochondrial Complex I

Overview
Journal PLoS One
Date 2012 May 5
PMID 22558363
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Short-chain quinones have been investigated as therapeutic molecules due to their ability to modulate cellular redox reactions, mitochondrial electron transfer and oxidative stress, which are pathologically altered in many mitochondrial and neuromuscular disorders. Recently, we and others described that certain short-chain quinones are able to bypass a deficiency in complex I by shuttling electrons directly from the cytoplasm to complex III of the mitochondrial respiratory chain to produce ATP. Although this energy rescue activity is highly interesting for the therapy of disorders associated with complex I dysfunction, no structure-activity-relationship has been reported for short-chain quinones so far. Using a panel of 70 quinones, we observed that the capacity for this cellular energy rescue as well as their effect on lipid peroxidation was influenced more by the physicochemical properties (in particular logD) of the whole molecule than the quinone moiety itself. Thus, the observed correlations allow us to explain the differential biological activities and therapeutic potential of short-chain quinones for the therapy of disorders associated with mitochondrial complex I dysfunction and/or oxidative stress.

Citing Articles

Leber's hereditary optic neuropathy - current status of idebenone and gene replacement therapies.

Klopstock T, Zeng L, Priglinger C Med Genet. 2025; 37(1):57-63.

PMID: 39963374 PMC: 11831234. DOI: 10.1515/medgen-2024-2066.


Targeting Ferroptosis in Parkinson's Disease: Mechanisms and Emerging Therapeutic Strategies.

Zhou M, Xu K, Ge J, Luo X, Wu M, Wang N Int J Mol Sci. 2024; 25(23).

PMID: 39684753 PMC: 11641825. DOI: 10.3390/ijms252313042.


Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities.

Gallo G, Rubattu S, Volpe M Int J Mol Sci. 2024; 25(5).

PMID: 38473911 PMC: 10932393. DOI: 10.3390/ijms25052667.


Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy.

Aleo S, Del Dotto V, Romagnoli M, Fiorini C, Capirossi G, Peron C Cell Rep Med. 2024; 5(2):101383.

PMID: 38272025 PMC: 10897523. DOI: 10.1016/j.xcrm.2023.101383.


Clinical Approaches for Mitochondrial Diseases.

Hong S, Kim S, Kim K, Lee H Cells. 2023; 12(20).

PMID: 37887337 PMC: 10605124. DOI: 10.3390/cells12202494.


References
1.
Esposti M, Ngo A, Ghelli A, Benelli B, Carelli V, McLennan H . The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996; 330(2):395-400. DOI: 10.1006/abbi.1996.0267. View

2.
Carelli V, La Morgia C, Valentino M, Rizzo G, Carbonelli M, De Negri A . Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011; 134(Pt 9):e188. DOI: 10.1093/brain/awr180. View

3.
Tsuruo Y, Ishimura K, Tamura M, Kagawa S, Morita K . Biochemical and histochemical studies of the effects of cerebral metabolism-improving drugs on NADPH diaphorase activity in mouse brain. Jpn J Pharmacol. 1994; 65(3):285-8. DOI: 10.1254/jjp.65.285. View

4.
Haginoya K, Miyabayashi S, Kikuchi M, Kojima A, Yamamoto K, Omura K . Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol Sci. 2008; 278(1-2):112-4. DOI: 10.1016/j.jns.2008.11.008. View

5.
Rauchova H, Vrbacky M, Bergamini C, Fato R, Lenaz G, Houstek J . Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Commun. 2005; 339(1):362-6. DOI: 10.1016/j.bbrc.2005.11.035. View